title: [Effects of probiotic bifiform on efficacy of Helicobacter pylori infection treatment].
abstract: OBJECTIVE
  To study effects of the probiotic bifiform on efficacy of Helicobacter pylori (HP) eradication in patients with chronic gastritis and ulcer disease.
  
  
  METHODS
  A total of 98 patients with verified HP infection were divided into two groups. The study group received a week three-component anti-HP therapy+a probiotic. The control group received the same treatment without the probiotic. All the patients were tested for HP before the treatment and one month after the end of the treatment. Cell composition of duodenal mucosa (DM), tissue proinflammatory cytokines, secretory immunoglobulin A (sIgA) in coprofiltrates, serum IgA, IgM, IgG, phagocytic parameters and copromicrobiology were studied.
  
  
  RESULTS
  HP eradication rate in the study group was higher than in the control group (89.1 vs 63.5, respectively, p < 0.05). After the treatment, patients of the study group had lower rates of side effects, impaired intestinal biocenosis, tissue cytokines levels but higher concentration of plasmatic cells in CO and cIgA in coprofiltrates.
  
  
  CONCLUSIONS
  The addition of probiotic bifiform to the standard three-component antihelicobacter scheme of the treatment raises its efficacy and is promising treatment of HP. Mechanisms of a potentiating action of the probiotic are related to enhancement of antibacterial activity of local immune reactions.
authors.forename: E P
authors.initials: EP
authors.lastname: Iakovenko
authors.forename: P Ia
authors.initials: PIa
authors.lastname: Grigor'ev
authors.forename: A V
authors.initials: AV
authors.lastname: Iakovenko
authors.forename: N A
authors.initials: NA
authors.lastname: Agafonova
authors.forename: A S
authors.initials: AS
authors.lastname: Prianishnikova
authors.forename: E N
authors.initials: EN
authors.lastname: Sheregova
authors.forename: I V
authors.initials: IV
authors.lastname: Vasil'ev
authors.forename: Iu V
authors.initials: IuV
authors.lastname: Komleva
authors.forename: I V
authors.initials: IV
authors.lastname: Oprishchenko
authors.forename: V A
authors.initials: VA
authors.lastname: Anashkin
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000907:Antibodies, Bacterial / Q000276:immunology; D001644:Bifidobacterium; D005260:Female; D005500:Follow-Up Studies; D005753:Gastric Mucosa / Q000382:microbiology; D005756:Gastritis / Q000188:drug therapy / Q000382:microbiology; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects / Q000276:immunology / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008875:Middle Aged; D019936:Probiotics / Q000627:therapeutic use*; D013276:Stomach Ulcer / Q000188:drug therapy / Q000382:microbiology; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000907:Antibodies, Bacterial